Javascript must be enabled to continue!
mTOR pathway inhibition stimulates pharmacologically induced nonsense suppression
View through CrossRef
ABSTRACTA large number of human genetic diseases result from premature termination codons (PTCs) caused by splicing defects, insertions, deletions or point mutations also termed nonsense mutations. Nonsense mutations are the source of various genetic diseases, ranging from rare neuro-metabolic disorders to relatively common inheritable cancer syndromes and muscular dystrophies. Over the years, a wide spectrum of studies has shown that certain antibiotics and other synthetic molecules can act as nonsense mutation suppressors, by inducing readthrough of the stop-codon leading to the expression of a full-length protein. Unfortunately, most readthrough-inducing agents have limited effects and are toxic. Thus, efforts are made to improve the clinical outcome of nonsense mutation suppressors.Here we show that the mTOR pathway is involved in antibiotic-mediated readthrough of nonsense mutations at the level of protein translation initiation. We demonstrate that inhibition of the mTOR translation-initiation-controlling eIF4E branch induces antibiotic-mediated nonsense mutation readthrough, paving the way to the development of a novel therapeutic strategy for enhancing the restoration of these disease-causing mutated transcripts.
Cold Spring Harbor Laboratory
Title: mTOR pathway inhibition stimulates pharmacologically induced nonsense suppression
Description:
ABSTRACTA large number of human genetic diseases result from premature termination codons (PTCs) caused by splicing defects, insertions, deletions or point mutations also termed nonsense mutations.
Nonsense mutations are the source of various genetic diseases, ranging from rare neuro-metabolic disorders to relatively common inheritable cancer syndromes and muscular dystrophies.
Over the years, a wide spectrum of studies has shown that certain antibiotics and other synthetic molecules can act as nonsense mutation suppressors, by inducing readthrough of the stop-codon leading to the expression of a full-length protein.
Unfortunately, most readthrough-inducing agents have limited effects and are toxic.
Thus, efforts are made to improve the clinical outcome of nonsense mutation suppressors.
Here we show that the mTOR pathway is involved in antibiotic-mediated readthrough of nonsense mutations at the level of protein translation initiation.
We demonstrate that inhibition of the mTOR translation-initiation-controlling eIF4E branch induces antibiotic-mediated nonsense mutation readthrough, paving the way to the development of a novel therapeutic strategy for enhancing the restoration of these disease-causing mutated transcripts.
Related Results
Role of mTOR in Hematopoiesis and Hematopoietic Stem Cell Regulation.
Role of mTOR in Hematopoiesis and Hematopoietic Stem Cell Regulation.
Abstract
Abstract 1490
Poster Board I-513
The mammalian target of rapamycin (mTOR) integrates nutrients, growth factors, and cellular e...
Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential
Target for Cancer Intervention: A Short Overview
Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential
Target for Cancer Intervention: A Short Overview
Background:
The mammalian role of the rapamycin (mTOR) pathway is the practical nutrient-sensitive regulation of animal growth and plays a central role in physiology, metabolism, a...
Abstract 1692: mTOR inhibition attenuates chemosensitivity through induction of a persister state
Abstract 1692: mTOR inhibition attenuates chemosensitivity through induction of a persister state
Abstract
Effective cancer therapeutics often kill a large fraction of tumor cells, while sparing a small surviving population, which can resurface as future tumor re...
SARS-CoV-2 S protein activates the HIV latent reservoir through the mTOR pathway
SARS-CoV-2 S protein activates the HIV latent reservoir through the mTOR pathway
Abstract
During the global COVID-19 pandemic, mRNA vaccines using the S protein as antigen were widely used.Vaccine-induced S proteins can persist in vivo for weeks, tr...
Abstract 1555: Use of a mouse model of constitutive mTOR inhibition to identify molecular modulators of acquired resistance.
Abstract 1555: Use of a mouse model of constitutive mTOR inhibition to identify molecular modulators of acquired resistance.
Abstract
The AKT/PI3K/mTOR signaling pathway is hyperactivated in cancers, including both solid tumors and hematologic malignancies. This hyperactivation is often du...
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract 1716: Evaluating the functional impacts of the BRCA1-mTORC2 interaction in breast cancer
Abstract
Objective: The BRCA1 C-Terminal (BRCT) domain of BRCA1 has been found to interact with three accessory proteins (PRR5, RICTOR, and SIN1) of mTOR complex 2 (...
Abstract 4697: The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
Abstract 4697: The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
Abstract
The chromatin remodeling SWI/SNF complex is mutated in 20% of all cancers and ARID1A is the most frequently mutated subunit. However, the tumor suppressive ...
Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract 1674: Inhibition of GSK3 reduces p70S6K activity and promotes autophagy independently of the JNK-cJun pathway.
Abstract
Considering that a tumor promoting role for GSK3 has been suggested in pancreatic cancer (PC) cells and that GSK3 inhibitors are currently under clinical tr...

